What happened
Telcon RF Pharmaceutical reported consolidated results for FY2025: revenue of US$29.1M (+13.99% year on year), operating profit of US$471K (from a loss a year earlier) and a net loss of US$7.89M.
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$29.1M |
|---|---|
| Revenue vs a year earlier | +13.99% |
| Operating profit | US$471K |
| Net income | −US$7.89M |
| Period | FY2025 (consolidated) |
| Filed | 2026-03-04, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260304901140 → open original filing |
Source: DART. Information only, not investment advice.